NeuroOne Medical Technologies Corporation operates as a medical technology company. It focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and other related brain related disorders. NeuroOne Medical Technologies Corporation has a strategic partnership with RBC Medical Innovations to develop and manufacture a radiofrequency generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
IPO Year:
Exchange: NASDAQ
Website: n1mtc.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/29/2022 | $6.00 → $2.00 | Buy → Hold | Craig Hallum |
| 12/3/2021 | $5.75 | Buy | Alliance Global Partners |
| 11/15/2021 | $6.00 | Buy | Craig-Hallum |
EDEN PRAIRIE, MN / ACCESSWIRE / November 13, 2024 / NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will be participating in the Virtual Investor Summit Microcap Event. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.Event: Q4 Investor SummitDate: Thursday, November 21, 2024Presentation Time: 1:30pm - 2:00pm ETLocation: https://www.webcaster4.com/Webcast/Page/3075/51590The theme is 40 micro-cap companies with a catalyst and/or strong perform
License Provides Exclusive Commercialization Rights for US Distribution and Certain OUS MarketsAgreement expected to boost NeuroOne sales revenue and profitability EDEN PRAIRIE, Minn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the execution of an amendment to its existing distribution agreement with Zimmer Biomet that will provide Zimmer Biomet with certain exclusive rights to distribute NeuroOne's OneRF™ Ablation System for use in the brain. NeuroOne will
EDEN PRAIRIE, Minn., Oct. 24, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies. Ron McClurg, CFO, will be presenting at 9:00 am ET on October 30th. The Company will also hold one-
Minimally invasive technology would allow for percutaneous placement of a paddle electrode Renowned pain specialist Dr. Sean Li to present on this innovative tool for lower back pain EDEN PRAIRIE, Minn., Sept. 24, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that its percutaneous paddle technology will be featured at The Business of Pain Meeting September 26th – 29th at the Loew's Vanderbilt Hotel in Nashville, TN. Dr. Sean Li, course director and expert in pain manageme
Forty-four ablations performed successfully in one patient Patient currently reportedly seizure free with improvements in mood and memory EDEN PRAIRIE, Minn., Sept. 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the OneRF Ablation System was recently used in a breakthrough patient procedure at the University Hospitals in Cleveland to successfully complete forty four ablations in one patient. In mid-July, led by Dr. Michael Staudt, Neurosurgeon, a patient ben
EDEN PRAIRIE, Minn., Sept. 05, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its upcoming virtual investor presentation at the H.C. Wainwright 26th Annual Global Investment Conference being held in-person and virtually on September 9-11, 2024. The Company's virtual presentation by Chief Operating Officer Chris Volker will be available on demand beginning at 7:00 a.m. ET on Monday, September 9, 2024, through the end of the conference. To access the presentation, investors ca
EDEN PRAIRIE, Minn., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the third quarter fiscal year 2024 ended June 30, 2024. Third Quarter Fiscal Year 2024 and Recent Business Updates Financial Highlights: Product revenue of $826,000 in Q3 2024, compared to $630,000 in Q3 2023Reduced operating expenses from $3.8 million in Q3 2023 to $3.1 million in Q3 2024Raised an additional $1.6 million using the ATM Program in Q3 2024Completed $2
EDEN PRAIRIE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on August 14, 2024, at 4:30 PM Eastern Time to discuss financial results for its third quarter of fiscal year 2024 ended June 30, 2024, and provide a corporate update. Conference Call and Webcast Information: Wednesday, August 14, 2024 – 4:30 PM Eastern Time Participants: Toll Free: 877-545-0320International: 973-528-0002Participant Access Code: 579769 Phone Replay:
Proceeds to be used for OneRF commercialization activities and to bridge the Company to the close of a potential distribution arrangement with a strategic partner currently in the diligence process EDEN PRAIRIE, Minn., Aug. 05, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the closing of a $2.65 million private placement, as well as access to an additional $3 million credit facility. In addition, the Company announced that it signed a term sheet with an undisclosed global m
Five ablations performed successfully in one patient Procedure performed at patient's bedside saving time and cost associated with the operating room EDEN PRAIRIE, Minn., June 25, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the OneRF Ablation System was recently used at a prestigious hospital located in Jacksonville, Florida to successfully complete five ablations in one patient. The patient was suffering from multifocal epilepsy, a condition whereby seizures are t
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
SCHEDULE 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)
8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
EFFECT - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
S-3/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
S-3 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
EFFECT - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
424B5 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
D - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)
SC 13G - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)
SC 13G - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)
SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)
Craig Hallum downgraded Numerical Tech from Buy to Hold and set a new price target of $2.00 from $6.00 previously
Alliance Global Partners initiated coverage of NeuroOne Medical Tech with a rating of Buy and set a new price target of $5.75
Craig-Hallum initiated coverage of NeuroOne Medical Tech with a rating of Buy and set a new price target of $6.00
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has appointed medtech executive Christopher R. Volker as Chief Operating Officer. Mr. Volker joins NeuroOne from Abbott Laboratories which acquired Cardiovascular Systems, Inc. in April 2023. Mr. Volker held the role of Vice President and General Manager of International at
EDEN PRAIRIE, Minn., Jan. 18, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announces the appointment of Chad Wilhelmy, as Vice President of Quality Control and Regulatory Affairs. Mr. Wilhelmy joins NeuroOne from HLT Medical, a subsidiary of the Bracco Group, where he was the Vice President Quality Assurance. Dave Rosa, CEO of NeuroOne Medical Technologies Corporation says, "Chad's appointment further strengthens our executive leadership team and deepens our capabilities as we build the pla
Five ablations performed successfully in one patient Procedure performed at patient's bedside saving time and cost associated with the operating roomEDEN PRAIRIE, Minn., June 25, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the OneRF Ablation System was recently used at a prestigious hospital located in Jacksonville, Florida to successfully complete five ablations in one patient.
ICD-10-PCS code for first to market, FDA-cleared thin-film, sEEG-guided RF ablation system effective October 1, 2024 Specific procedure code positions OneRF™ Ablation System for broader adoption and awareness throughout the healthcare system
NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 10 percent decrease over losses of $(0.10) per share from the same period last year. The company reported $1.38 million in sales this quarter. This is a 195.38 percent increase over sales of $466.18 thousand the same period last year.
First to market FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benefit of temperature control
Gainers Regencell Bioscience (NASDAQ:RGC) shares rose 130.9% to $10.39 during Monday's regular session. The company's market cap stands at $135.2 million. TC BioPharm (Holdings) (NASDAQ:TCBP) shares increased by 76.41% to $1.87. The company's market cap stands at $4.5 million. bioAffinity Technologies (NASDAQ:BIAF) shares moved upwards by 28.1% to $1.96. The company's market cap stands at $21.8 million. Graphite Bio (NASDAQ:GRPH) stock moved upwards by 25.47% to $3.94. The market value of their outstanding shares is at $229.4 million. ASLAN Pharma (NASDAQ:ASLN) shares rose 24.8% to $0.78. The company's market cap stands at $13.0 million. Mesoblast (NASDAQ:MESO) stock rose 22.79% to $2.
Gainers Cogent Biosciences (NASDAQ:COGT) stock increased by 64.0% to $8.96 during Wednesday's regular session. The company's market cap stands at $771.2 million. Larimar Therapeutics (NASDAQ:LRMR) shares increased by 45.53% to $12.72. The company's market cap stands at $558.4 million. BioXcel Therapeutics (NASDAQ:BTAI) stock rose 35.2% to $3.33. The company's market cap stands at $101.0 million. Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 31.26% to $10.91. The company's market cap stands at $140.1 million. Electromed (AMEX:ELMD) stock rose 22.61% to $12.43. The market value of their outstanding shares is at $106.6 million. As per the news, the Q2 earnings report came out
Gainers FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) shares increased by 25.0% to $17.43 during Tuesday's after-market session. Sonnet BioTherapeutics (NASDAQ:SONN) stock moved upwards by 13.46% to $1.77. The company's market cap stands at $5.4 million. GlucoTrack (NASDAQ:GCTK) stock rose 12.19% to $0.23. The company's market cap stands at $4.8 million. Clene (NASDAQ:CLNN) shares moved upwards by 9.92% to $0.47. The market value of their outstanding shares is at $59.7 million. Larimar Therapeutics (NASDAQ:LRMR) shares moved upwards by 8.69% to $9.5. The company's market cap stands at $417.1 million. BiomX (AMEX:PHGE) shares rose 6.83% to $0.24. The company's market cap stands at $
EDEN PRAIRIE, Minn., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the third quarter fiscal year 2024 ended June 30, 2024. Third Quarter Fiscal Year 2024 and Recent Business Updates Financial Highlights: Product revenue of $826,000 in Q3 2024, compared to $630,000 in Q3 2023Reduced operating expenses from $3.8 million in Q3 2023 to $3.1 million in Q3 2024Raised an additional $1.6 million using the ATM Program in Q3 2024Completed $2
EDEN PRAIRIE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on August 14, 2024, at 4:30 PM Eastern Time to discuss financial results for its third quarter of fiscal year 2024 ended June 30, 2024, and provide a corporate update. Conference Call and Webcast Information: Wednesday, August 14, 2024 – 4:30 PM Eastern Time Participants: Toll Free: 877-545-0320International: 973-528-0002Participant Access Code: 579769 Phone Replay:
EDEN PRAIRIE, Minn., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the second quarter fiscal year 2024 ended March 31, 2024. Second Quarter Fiscal Year 2024 and Recent Business Updates Financial Highlights: Product revenue of $1,377,000 in Q2 2024, compared to $466,000 in Q2 2023Raised an additional $2.0 million using the ATM Program in Q2 2024 Evo® sEEG: Zimmer Biomet continued to expand into new a
EDEN PRAIRIE, Minn., May 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on May 14, 2024 at 4:30 PM Eastern Time to discuss financial results for its second quarter of fiscal year 2024 ended March 31, 2024, and provide a corporate update. Conference Call and Webcast Information: Tuesday, May 14, 2024 – 4:30 PM Eastern Time Participant Dial-In:Toll Free: 888-506-0062International: 973-528-0011Access Code: 489972 Live Webcast: Join here.
EDEN PRAIRIE, Minn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the first quarter fiscal year 2024 ended December 31, 2023. First Quarter Fiscal Year 2024 and Recent Business UpdatesFinancial Highlights: Product revenue of $978,000 in Q1 2024, compared to $115,000 in Q1 2023 Raised an additional $2.8 million using the ATM Offering in December 2023 and January 2024 Evo® sEEG: Customer feedback remains positive as commercial la
EDEN PRAIRIE, Minn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on February 13, 2024 at 4:30 PM Eastern Time to discuss financial results for its first quarter of fiscal year 2024 ended December 31, 2023, and provide a corporate update. Conference Call and Webcast Information: Tuesday, February 13, 2024 – 4:30 PM Eastern Time Participant Dial-In:888-506-0062 / +1 973-528-0011 Access Code: 540724 Live Webcast: Join here.
EDEN PRAIRIE, Minn., Dec. 07, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fourth quarter and fiscal year ended September 30, 2023, and provide a corporate update, on December 14, 2023 at 5:00 PM Eastern Time. Conference Call and Webcast Information: Thursday, December 14, 2023 – 5:00 PM Eastern Time Participant Dial-In:877-405-1216 / +1 201-689-8336 Live Webcast: Join here. Phone Replay: 877-660-6853 / 201-612-7
EDEN PRAIRIE, Minn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its third quarter 2023 ended June 30, 2023 and provide a corporate update on August 14, 2023 at 4:30 PM Eastern Time. Conference Call and Webcast Information: Monday, August 14, 2023 – 4:30 PM Eastern Time Participant Dial-In:800-267-6316 / +1 203-518-9783Conference ID (required for entry): NEURO Live Webcast: Join here. Phone Replay: 877-660-
EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the fiscal second quarter 2023 ended March 31, 2023. Fiscal Second Quarter 2023 and Recent Business Updates Evo® sEEG: Announced the commercial launch of the Evo sEEG electrode product line in the United States with exclusive distribution partner Zimmer Biomet. The new technology potentially provides NeuroOne with a new revenue stream.The first clinical case us
EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fiscal second quarter 2023 ended March 31, 2023 and provide a corporate update on May 11, 2023 at 4:30 PM Eastern Time. Conference Call and Webcast Information: Thursday, May 11, 2023 – 4:30 PM Eastern Time Participant Dial-In:888-645-4404 / 862-298-0702 Live Webcast: Join here. Phone Replay: 877-660-6853 / 201-612-7415, Access ID: 13738525